Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04999826 · ClinicalTrials.gov registry record
Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 105
- Enrollment target
NCT04999826: Completed study, sponsored by Mayo Clinic.
NCT04999826 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04999826 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
This study gathers information to create a database to improve the ability to diagnose cancer, predict long term health of breast cancer patients, and help develop future treatment products. This study will provide a foundational platform for therapeutic development and intervention studies in the future and may for therapeutic development and intervention studies in the future, and may advance researchers understanding of the contribution gut bacteria to altered circulating estrogens in breast cancer survivors.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2022-12-30 |
What the finished NCT04999826 record still lists
NCT04999826 is an observational study that tracks outcomes without assigning an intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT04999826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04999826 about?
NCT04999826 is a clinical study titled "Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors". This study gathers information to create a database to improve the ability to diagnose cancer, predict long term health of breast cancer patients, and help develop future treatment products. This study will provide a foundational platform for therapeutic development and intervention studies in the f...
What is the current status of trial NCT04999826?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2021-04-01. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT04999826?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT04999826?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI